This continuation of the San Francisco Bay Area Adult Glioma Survival Study builds on 16 years of R01funded population-based research and more than 20 years of P01 and 5 years of SPORE funded clinic-based research in the UCSF Neuro-oncology Clinic (NOC); together we have among the country's largestdatasets of well-characterized adult glioma patients with polymorphism, serologic, tumor marker,demographic and other epidemiologic, treatment, and survival data. The identification of relevant tumor,serologic, constitutive polymorphic markers and patient characteristics related to glioma survival is likely toaid in choosing the best treatments for each glioma patient, in enhancing definition of homogeneoussubgroups for clinical trials based on uniform prognosis for rapid treatment evaluation, and in providing betterprognostic information to patients. Several markers identified in our ongoing and other studies warrantfurther research. The study's specific aims are to: (1) Continue to (a) determine vital status and relevanttreatment information for population based adult onset glioma cases diagnosed 1997-99 and 2001-04 andpatients accrued through the UCSF NOC 2002-2006 (total number -1500) and (b) accrue -720patients(questionnaire, blood, buccal, and tumor specimens) in the UCSF NOC 2007-2011. (Another populationbased series to begin May 2006 will bring the total number of patients diagnosed from 2006-2011 to -960).(2) Obtain a greater understanding of the mechanisms of improved survival among glioblastoma cases withelevated versus normal or borderline IgE levels observed in our current series and validate and expandfindings to other potentially related serum markers (sCD23 and sCD14), tumor markers (CD23 protein andIL13RA2 m-RNA expression), and constitutive SNPs in IL4, IL13, IL4R, IL13RA1, and IL13RA2. Thesemarkers will also be assessed in relation to tumor TP53 mutation and expression and EGFR amplificationand expression (markers measured in the parent study). (3) Determine whether polymorphisms in MGMT ortumor TP53 mutation or expression influence survival in the presence of absence of tumor MGMTmethylation in patients treated with temozolomide. (4) Validate promising markers obtained from aims 2 and3 in newly diagnosed patients seen at the UCSF NOC from July 1, 2007-June 30, 2011 in -100of these GMcases on clinical trial protocols. Our study group collaborates extensively with other brain SPORE programsand the Brain Tumor Epidemiology Consortium through sharing of specimens and data and joint grant andpaper writing.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA097257-06
Application #
7253800
Study Section
Special Emphasis Panel (ZCA1-RPRB-7 (J1))
Project Start
2007-05-01
Project End
2012-04-30
Budget Start
2007-05-01
Budget End
2008-04-30
Support Year
6
Fiscal Year
2007
Total Cost
$321,228
Indirect Cost
Name
University of California San Francisco
Department
Type
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Choi, Serah; Yu, Yao; Grimmer, Matthew R et al. (2018) Temozolomide-associated hypermutation in gliomas. Neuro Oncol 20:1300-1309
Jacobs, Daniel I; Liu, Yanhong; Gabrusiewicz, Konrad et al. (2018) Germline polymorphisms in myeloid-associated genes are not associated with survival in glioma patients. J Neurooncol 136:33-39
Berntsson, Shala G; Merrell, Ryan T; Amirian, E Susan et al. (2018) Glioma-related seizures in relation to histopathological subtypes: a report from the glioma international case-control study. J Neurol 265:1432-1442
Goode, Benjamin; Joseph, Nancy M; Stevers, Meredith et al. (2018) Adenomatoid tumors of the male and female genital tract are defined by TRAF7 mutations that drive aberrant NF-kB pathway activation. Mod Pathol 31:660-673
Hayes, Josie; Yu, Yao; Jalbert, Llewellyn E et al. (2018) Genomic analysis of the origins and evolution of multicentric diffuse lower-grade gliomas. Neuro Oncol 20:632-641
Ostrom, Quinn T; Kinnersley, Ben; Armstrong, Georgina et al. (2018) Age-specific genome-wide association study in glioblastoma identifies increased proportion of 'lower grade glioma'-like features associated with younger age. Int J Cancer 143:2359-2366
Pekmezci, Melike; Stevers, Meredith; Phillips, Joanna J et al. (2018) Multinodular and vacuolating neuronal tumor of the cerebrum is a clonal neoplasm defined by genetic alterations that activate the MAP kinase signaling pathway. Acta Neuropathol 135:485-488
Behr, Spencer C; Villanueva-Meyer, Javier E; Li, Yan et al. (2018) Targeting iron metabolism in high-grade glioma with 68Ga-citrate PET/MR. JCI Insight 3:
Taylor, Jennie W; Parikh, Mili; Phillips, Joanna J et al. (2018) Phase-2 trial of palbociclib in adult patients with recurrent RB1-positive glioblastoma. J Neurooncol 140:477-483
Luks, Tracy L; McKnight, Tracy Richmond; Jalbert, Llewellyn E et al. (2018) Relationship of In Vivo MR Parameters to Histopathological and Molecular Characteristics of Newly Diagnosed, Nonenhancing Lower-Grade Gliomas. Transl Oncol 11:941-949

Showing the most recent 10 out of 362 publications